Cornelius VR, Liu K, Peacock J, Sharma M, Sauzet O. Useablity of Harm Profile Data in Product Descriptions: A Comparison between the US and Europe. In: Abstracts of the 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, October 24–27, 2014, Taipei, Taiwan. Pharmacoepidemiology and Drug Safety. Vol 23. Hoboken: Wiley Blackwell (John Wiley & Sons); 2014: 235-235
Medication-related adverse events are a major cause of disability and death,1 and one of the most co...
Objective: To determine whether the use of verbal descriptors suggested by the European Union (EU) s...
Comparative cross national (CNC) drug utilization studies are challenging. However, there can be con...
Good information on the harm of a drug is vital to inform risk-benefit decisions and undertake robus...
Cornelius VR, Liu K, Peacock J, Sauzet O. Variation in adverse drug reactions listed in product info...
OBJECTIVE: To compare consistency of adverse drug reaction (ADR) data in publicly available product ...
The safety information on drug labels of a company marketing the same drugs in different countries i...
In 1968 the World Health Organisation initiated the development of an international programme for co...
The aim of the study was to assess the clinical pharmacology information provided in the summaries o...
Objective: To compare the tools, terminologies and systems used by poisons centres’ (PCs) to record...
The desire to reduce human exposure to toxic chemicals associated with consumer products that are ma...
BACKGROUND: Observational pharmacoepidemiological (PE) studies on drug safety have produced discrepa...
BACKGROUND: Observational pharmacoepidemiological (PE) studies on drug safety have produced discrepa...
BACKGROUND: Observational pharmacoepidemiological (PE) studies on drug safety have produced discrepa...
Background Availability of data on the external causes of injuries/accidents which includes produc...
Medication-related adverse events are a major cause of disability and death,1 and one of the most co...
Objective: To determine whether the use of verbal descriptors suggested by the European Union (EU) s...
Comparative cross national (CNC) drug utilization studies are challenging. However, there can be con...
Good information on the harm of a drug is vital to inform risk-benefit decisions and undertake robus...
Cornelius VR, Liu K, Peacock J, Sauzet O. Variation in adverse drug reactions listed in product info...
OBJECTIVE: To compare consistency of adverse drug reaction (ADR) data in publicly available product ...
The safety information on drug labels of a company marketing the same drugs in different countries i...
In 1968 the World Health Organisation initiated the development of an international programme for co...
The aim of the study was to assess the clinical pharmacology information provided in the summaries o...
Objective: To compare the tools, terminologies and systems used by poisons centres’ (PCs) to record...
The desire to reduce human exposure to toxic chemicals associated with consumer products that are ma...
BACKGROUND: Observational pharmacoepidemiological (PE) studies on drug safety have produced discrepa...
BACKGROUND: Observational pharmacoepidemiological (PE) studies on drug safety have produced discrepa...
BACKGROUND: Observational pharmacoepidemiological (PE) studies on drug safety have produced discrepa...
Background Availability of data on the external causes of injuries/accidents which includes produc...
Medication-related adverse events are a major cause of disability and death,1 and one of the most co...
Objective: To determine whether the use of verbal descriptors suggested by the European Union (EU) s...
Comparative cross national (CNC) drug utilization studies are challenging. However, there can be con...
.jpg%3Fwidth%3D300&w=3840&q=75)
Add to ORKG